Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Dexcom, the San Diego-based maker of continual glucose monitors for diabetes patients and pre-diabetics, announced Wednesday ...

Fintel reports that on August 21, 2025, Argus Research initiated coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation ...

With a new CEO taking over in 2026, Dexcom aims to stay ahead of its CGM competitors through a combination of innovation and ...

Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and ...

The medical technology company reported earnings per share of $0.48, significantly surpassing the $0.45 consensus estimate. Revenue reached $1.16 billion, exceeding projections of $1.12 billion. This ...

NasdaqGS:DXCM 1 Year Share Price vs Fair Value Explore DexCom's Fair Values from the Community and select yours If ...

Over the last six months, DexCom’s shares have sunk to $80.25, producing a disappointing 9.9% loss - a stark contrast to the ...

DexCom has been able to restore its inventory to more favorable levels through higher levels of production and expedited shipping over the last 12 months.

Data from Dexcom CGMs will be integrated into FriskaAi and will be monitored by AI-powered algorithms that alert patients ...

The Federal Circuit upheld an administrative tribunal’s decision to nix six claims from a DexCom Inc. patent covering implantable sensors used to monitor patients’ blood glucose levels.

System integrates glucose biosensor with an AI-driven platform to show how food, activity, stress, sleep affect the body in ...